/ BHVN
Why Did Biohaven Stock Collapse in Premarket Today? FDA Rejects Its Lead Drug Vyglxia
Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as data showed slower disease ...
November 05, 2025